Cafepharma | Pharmaceutical Sales, Medical Sales, Lab Sales

Cafepharma Today

November 29 2023 - FDA names chief scientist Bumpus as Woodcock’s successor

FDA names chief scientist Bumpus as Woodcock’s successor
FDA launches probe of malignancies linked to CAR-T therapies
FDA kicks off review of Karuna’s schizophrenia drug KarXT
Lilly puts potential $660M on the line for protein-protein interaction blockers
*please scroll down for all the latest news*

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Walgreens to close most stores on Thanksgiving for first time

Axios

Monday, November 20, 2023 - 11:25am

tags:

Walgreens, employees, pharmacies

Is Novavax, the latecomer COVID vaccine, worth the wait?

Medical Marketing and Media

Monday, November 20, 2023 - 10:20am

tags:

Novavax, vaccines, COVID-19

5 Cancer Vaccines to Watch in 2024

BioSpace

Monday, November 20, 2023 - 10:15am

tags:

Merck, Moderna Therapeutics, melanoma, BioNTech, pancreatic cancer, OSE Immunotherapeutics, Transgene, non-small cell lung cancer, Nykode Therapeutics, cervical cancer

FDA to delay decision on Bristol Myers-2seventy bio cancer therapy

Reuters

Monday, November 20, 2023 - 10:12am

tags:

Bristol Myers Squibb, 2seventy bio, blood cancer, FDA, Abecma

AZ launches digital clinical trials business

Pharmaphorum

Monday, November 20, 2023 - 10:10am

tags:

AstraZeneca, clinical trials, Evinova

Servier’s vorasidenib proves efficacy in tumor growth reduction

Clinical Trials Arena

Monday, November 20, 2023 - 10:09am

tags:

Servier, vorasidenib, glioma, clinical trials

Playing in the Hot Obesity Market, Carmot Braves Chilly IPO Waters

BioSpace

Monday, November 20, 2023 - 10:07am

tags:

Carmot Therapeutics, obesity, IPOs

MSLs rejoice, overtaking sales reps as pharma’s prime information conveyors

Medical Marketing and Media

Sunday, November 19, 2023 - 9:38pm

tags:

MSLs, pharma reps, drug reps, pharma marketing

AstraZeneca’s AKT Inhibitor Wins FDA Approval for Combo Breast Cancer Treatment

BioSpace

Sunday, November 19, 2023 - 9:36pm

tags:

AstraZeneca, Truqap, breast cancer

Beyond insulin: Medical expands patient access to diabetes supplies

Medical Marketing and Media

Sunday, November 19, 2023 - 9:34pm

tags:

insulin, diabetes, Medi-Cal

FDA panel flags insufficient data for Merck's chronic cough drug

Reuters

Sunday, November 19, 2023 - 9:32pm

tags:

Merck, FDA, chronic cough, gefapixant

Breakthroughs in Medtech: 5 Leaders Share Their Secrets to Innovation

Medical Devices and Diagnostics Industry

Sunday, November 19, 2023 - 9:30pm

tags:

Medtech, innovation

Merck Expands Keytruda’s Label as a First-Line Option for Gastric Cancer

BioSpace

Friday, November 17, 2023 - 11:47am

tags:

Merck, Keytruda, gastric cancer

Novo Nordisk offers staff free Wegovy

Beckers Hospital Review

Friday, November 17, 2023 - 11:46am

tags:

Novo Nordisk, Wegovy, employee benefits

Karuna keeps $6B sales forecast alive with blood pressure data on schizophrenia drug

Fierce Biotech

Friday, November 17, 2023 - 11:31am

tags:

Karuna Therapeutics, KarXT, blood pressure, schizophrenia

Post hoc analysis of SCORED trial sheds positive light on Inpefa for heart failure

Clinical Trials Arena

Friday, November 17, 2023 - 11:29am

tags:

Lexicon Pharmaceuticals, Inpefa, clinical trials, heart failure, AHA

Xtandi cleared by FDA for earlier-stage prostate cancer

Pharmaphorum

Friday, November 17, 2023 - 10:10am

tags:

Pfizer, Astellas, Xtandi, prostate cancer, FDA

FDA Approves Truqap Plus Faslodex for Advanced HR-Positive Breast Cancer

Pharm Exec

Friday, November 17, 2023 - 10:09am

tags:

AstraZeneca, Truqap, breast cancer, HR-positive

What to know about the U.K.’s approval of the first CRISPR treatment for diseases

Nature

Friday, November 17, 2023 - 10:05am

tags:

UK, CRISPR, gene editing, Casgevy, Vertex Pharmaceuticals, CRISPR Therapeutics

FDA approves study of Versameb’s mRNA therapy in urinary incontinence

Clinical Trials Arena

Friday, November 17, 2023 - 10:03am

tags:

Versameb, MRNA, Stress Urinary Incontinence, FDA, clinical trials

Pages

Latest CP Wire Articles

First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study

Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth

Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Sapio Sciences launches new drug discovery platform

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

Why Medical and Pharma Sales Reps Should Start Their Own Senior Care Business

Bend Bioscience Adds Capacity and Technology Offerings with the Addition of New Process and Manufacturing Science Facility

Eastman introduces new excipient to formulate poorly soluble API

Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more

PharmaBlock Receives 2023 ACS CMO Excellence in Green Chemistry Award

Latest Pharmagather Articles

Drug Channels News Roundup, November 2023: My $0.02 on Express Scripts’ Cost-Based Pricing, Mark Cuban vs. PBMs, Dual-WAC Strategies, Pharmacy Shakeout, and Adam vs. Rocky

Drug Channels

Simplify and Accelerate Benefits Verification with a Fully Integrated, Adaptable Platform

Drug Channels

Medicare Part D in 2024: Mapping Large Chains' Position in 2024’s Preferred Pharmacy Networks

Drug Channels

Drug Channels Outlook 2024 (NEW Live Video Webinar)

Drug Channels

Four Trends That Are Shaping the Future of Market Access

Drug Channels

FDA’s OPDP Issues Two New Untitled Letters

eye on fda

Vertical Integration Lessons: The Economics and Strategies of Hospital-Owned Specialty Pharmacies

Drug Channels

Is Your Hub Partner Missing the Therapeutic Area Expertise You Need?

Drug Channels

Drug Channels News Roundup, October 2023: CVS & Humira Biosimilars, GLP-1 G2N Bubble, 340B Abuses, Rite Aid's Endgame, Mark Cuban Update, and an Epic Meetup

Drug Channels